GRAIL, Inc. (GRAL)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -264.07M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina.
U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering.
Every day, energy merchants collect and scrutinize whatever information they can find on fuel demand to get a trading edge: from satellite data tracking oil tankers worldwide to thermal images...
About GRAL
GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. Using our platform technology, we have developed a multi-cancer early detection blood test that has demonstrated in clin... [Read more...]
| CEO Hans E. Bishop | Employees 436 |
| Stock Exchange NASDAQ | Ticker Symbol GRAL |